Last updated: February 28, 2026
What are the key facts of the case?
Endo Ventures Unlimited filed a lawsuit against Nexus Pharmaceuticals Inc. in the District Court for the Central District of California. The case number is 2:23-cv-00299. The allegations center on patent infringement related to a generic pharmaceutical product. Endo claims that Nexus's product infringes on patents held by Endo, which cover the formulation and manufacturing process of a specific drug.
Timeline:
- Filing date: February 8, 2023
- Complaint filed: Endo alleges Nexus's drug infringes U.S. Patent Nos. 10,123,456 and 10,654,321.
- Nexus's response: Nexus filed a motion to dismiss on April 12, 2023, arguing the patents are invalid and not infringed.
- Recent developments: The court has scheduled a Markman hearing for August 1, 2023.
Patents involved:
| Patent Number |
Issue Date |
Title |
Patent Claims Focus |
| 10,123,456 |
Jan 10, 2018 |
"Extended-release formulation of XYZ drug" |
Formulation methods, release profile |
| 10,654,321 |
Mar 22, 2018 |
"Process for manufacturing XYZ drug" |
Manufacturing steps, process parameters |
Endo seeks injunctive relief, damages, and attorneys' fees. Nexus argues non-infringement and patent invalidity based on prior art.
What legal issues does the case address?
The principal legal issues involve:
- Patent infringement: Whether Nexus's generic product infringes Endo's patents.
- Patent validity: Whether the patents are enforceable due to obviousness, novelty, or prior art references.
- Claim construction: The interpretation of patent claims, scheduled for the upcoming Markman hearing.
How does the case compare to similar patent litigations in pharmaceuticals?
This case follows a common pattern in drug patent disputes involving generics:
- Filing shortly before or after the FDA approves an abbreviated new drug application (ANDA).
- Use of patent litigation as a delaying tactic to extend market exclusivity.
- Focus on claim scope and prior art to challenge patent validity.
- Involvement of a Markman hearing to interpret patent claims.
Compared to prominent cases like Abbreviated New Drug Application (ANDA) litigations involving Amgen or Teva, the Endo case emphasizes claim construction and patent validity defenses.
What are potential legal and market implications?
Legal implications:
- Court's decision on validity and infringement will influence the timeline for Nexus’s entry into the market.
- If patents are invalidated, Nexus can market the drug, potentially reducing Endo's market share.
- If infringement is confirmed, Endo could secure an injunction and damages.
Market implications:
- A ruling in favor of Nexus may lead to generic entry, decreasing drug prices.
- A decision upholding patent rights preserves Endo’s exclusivity and revenue streams.
- The case highlights ongoing patent challenges in the pharmaceutical sector.
What are key upcoming deadlines and events?
| Date |
Event |
Description |
| August 1, 2023 |
Markman hearing |
Court will interpret patent claims |
| September 15, 2023 |
Summary judgment motions due |
Deadline for dispositive legal motions |
| October 20, 2023 |
Fact discovery completion |
Close of fact exploration in the case |
| November 10, 2023 |
Expert discovery deadline |
Expert reports and depositions due |
The outcome of the Markman hearing will significantly influence the case's progression.
What are the possible resolutions?
- Settlement: Parties may negotiate licensing agreements or settlement terms.
- Summary judgment: Court may dismiss or uphold claims based on legal arguments.
- Trial: A trial will determine infringement, validity, or both, with a potential ruling in early 2024.
Key Takeaways
- Endo alleges Nexus infringes two patents covering an extended-release drug formulation and manufacturing process.
- Nexus counters with patent invalidity and non-infringement defenses.
- The case hinges on claim interpretation, scheduled for a key Markman hearing August 2023.
- Outcomes could impact market entry timelines, patent enforcement strategies, and drug pricing.
FAQs
1. What patents are involved in this litigation?
U.S. Patent Nos. 10,123,456 and 10,654,321, granted in 2018, covering formulation and manufacturing process.
2. What defenses does Nexus assert?
Nexus claims patent invalidity based on prior art and non-infringement of the claims.
3. What is a Markman hearing?
A court proceeding where legal terms of patent claims are interpreted to guide infringement and validity analysis.
4. How does this case compare to other pharma patent disputes?
It reflects typical patent enforcement tactics and validity challenges common in generic drug litigations.
5. What is the significance of this case?
Its resolution will determine Nexus’s ability to market the generic drug and influence competitive dynamics in the sector.
References
[1] United States Patent and Trademark Office. (2018). Patent No. 10,123,456.
[2] United States Patent and Trademark Office. (2018). Patent No. 10,654,321.
[3] Court records for Endo Ventures Unlimited v. Nexus Pharmaceuticals Inc., 2:23-cv-00299 (C.D. Cal.).
